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Abstract
People with severe mental illness (SMI) have reduced life expectancy compared with the
general population, which can be explained partly by their increased risk of diabetes. We
conducted a meta-analysis to determine the clinical effectiveness of pharmacological and
non-pharmacological interventions for improving glycaemic control in people with SMI
(PROSPERO registration: CRD42015015558). A systematic literature search was per-
formed on 30/10/2015 to identify randomised controlled trials (RCTs) in adults with SMI,
with or without a diagnosis of diabetes that measured fasting blood glucose or glycated hae-
moglobin (HbA1c). Screening and data extraction were carried out independently by two
reviewers. We used random effects meta-analysis to estimate effectiveness, and subgroup
analysis and univariate meta-regression to explore heterogeneity. The Cochrane Collabora-
tion’s tool was used to assess risk of bias. We found 54 eligible RCTs in 4,392 adults
(40 pharmacological, 13 behavioural, one mixed intervention). Data for meta-analysis
were available from 48 RCTs (n = 4052). Both pharmacological (mean difference (MD),
-0.11mmol/L; 95% confidence interval (CI), [-0.19, -0.02], p = 0.02, n = 2536) and beha-
vioural interventions (MD, -0.28mmol//L; 95% CI, [-0.43, -0.12], p<0.001, n = 956) were
effective in lowering fasting glucose, but not HbA1c (pharmacological MD, -0.03%; 95% CI,
[-0.12, 0.06], p = 0.52, n = 1515; behavioural MD, 0.18%; 95% CI, [-0.07, 0.42], p = 0.16, n =
140) compared with usual care or placebo. In subgroup analysis of pharmacological
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interventions, metformin and antipsychotic switching strategies improved HbA1c. Beha-
vioural interventions of longer duration and those including repeated physical activity had
greater effects on fasting glucose than those without these characteristics. Baseline levels
of fasting glucose explained some of the heterogeneity in behavioural interventions but not
in pharmacological interventions. Although the strength of the evidence is limited by inade-
quate trial design and reporting and significant heterogeneity, there is some evidence that
behavioural interventions, antipsychotic switching, and metformin can lead to clinically
important improvements in glycaemic measurements in adults with SMI.
Introduction
People with severe mental illness (SMI) (schizophrenia and other illnesses characterised by
psychosis) have a lower life expectancy compared with the general population by around 15 to
20 years [1]. A higher prevalence of comorbid conditions (e.g. diabetes and cardiovascular
disease) and poorer management of physical health contribute to this health inequality [2].
Around 13% of people with SMI have diabetes compared with 6% of the general population,
and the difference is increasing [3]. As diabetes interventions are scaled up for the general
population, these inequalities may increase further. This is because generic interventions are
unlikely to be suitable for people with SMI due to the complex combination of psychological,
social and financial barriers they face in managing their health [4].
Although there are more than 40 published systematic reviews of studies targeting physical
health in people with SMI, these have focused mainly on anthropological outcomes [5–8], with
few investigating diabetes prevention and treatment [9, 10]. It is well-established that modest
improvements in glycated haemoglobin (HbA1c) and blood glucose levels can avoid onset of
diabetes and have a significant impact on preventing diabetic complications in the general
population [11]. A few reviews have investigated the effect of pharmacological [6, 12] and
behavioural [7, 8, 13] interventions on these glycaemic measurements in people with SMI. An
older review investigated both pharmacological and behavioural interventions [14]. However
in all of these, glycaemic effects were examined as a secondary outcome only. This makes it dif-
ficult to determine which interventions are effective for improving glycaemic control in people
with SMI. The aim of this systematic review and meta-analysis is to identify pharmacological
and behavioural interventions for improving diabetes outcomes that have been tested in the




We included randomised controlled trials (RCTs) of interventions to improve diabetes out-
comes for adults (aged 18 years and over) with SMI. We defined SMI as schizophrenia, bipolar
disorder, psychosis or other non-organic psychotic disorders, including schizoaffective disor-
der and severe depression. To be included, studies had to measure at least one of the following
outcomes: i) in people without diabetes at baseline: incidence of diabetes, HbA1c or fasting glu-
cose; and ii) in people with diabetes at baseline: HbA1c, fasting glucose, weight, body mass
index (BMI), or diabetic complications.
We restricted studies to those published in peer reviewed journals and the English language.
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The protocol for the review has been published on the International Prospective Register of
Systematic Reviews (PROSPERO), registration number CRD42015015558 [15]. We carried
out the review in accordance with the PRISMA guidelines (see S1 PRISMA Checklist).
Search strategy
The search strategy comprised three concepts: ‘diabetes’, ‘SMI’, and ‘RCTs or systematic
reviews’. An example of the strategy is provided in the supporting information (see S1
Appendix).
Literature searches were performed in CINAHL (EBSCO); Embase Classic+Embase (Ovid);
PsycINFO (Ovid); Ovid Medline; PubMed; Cochrane Database of Systematic Reviews (Wiley)
and Central Register of Controlled Trials; Database of Abstracts of Reviews of Effect (Wiley);
and Conference Proceedings Citation Index (Thomson Reuters). We also searched three trial
registries (ClinicalTrials.gov, International Clinical Trials Registry Platform (WHO), ISRCTN
registry). Searches were performed on 12/12/2014, and updated on 30/10/2015 (except for trial
registries).
Study selection
Search results were managed in EndNote version 7 software. Citations and abstracts were
screened to exclude studies that did not meet the selection criteria. References of relevant
reviews identified during the screening process were also searched. Relevant full-text articles
were retrieved and assessed for eligibility; missing data to help assess eligibility were sought
from corresponding authors.
Data extraction and synthesis
Study characteristics and data for meta-analysis were extracted into a tailored and piloted data
collection form [15]. Multiple reports from the same study were linked and missing data were
requested from study authors. The Cochrane Collaboration tool was used to assess risk of bias
[16]. All stages of study selection and data extraction were conducted independently by two
reviewers, with discrepancies resolved through discussion and where consensus could not be
reached, arbitration by a third reviewer.
Due to the heterogeneity of diabetes interventions, we categorised interventions as pharma-
cological, non-pharmacological or mixed (interventions combining medication with a non-
pharmacological approach) [15]. Pharmacological interventions were further sub-grouped
into categories: i) diabetes medications (including metformin, sulphonylureas, insulin and
thiazolidinediones); ii) weight loss treatments (including antiparkinsonian, anticonvulsant
and antidepressant medications thought to promote weight loss, as well as anti-obesity drugs
and appetite suppressants); iii) combinations of weight loss and diabetes medications; iv)
switching antipsychotic medication; and v) an ‘other’ category.
Non-pharmacological interventions were categorised as behavioural (targeting a change in
an individual’s behaviour) or organisational (targeting a change in the environment or organi-
sation of care).
We planned to explore effectiveness of interventions in prevention of diabetes. However,
many studies did not distinguish between people with and without diabetes at baseline. Of the
studies that excluded people with diabetes at baseline, none measured incidence of diabetes or
reported data that would enable us to estimate this. We therefore pooled the results across all
studies for glycaemic control, using outcome data for HbA1c and fasting glucose.
We analysed pharmacological and non-pharmacological interventions separately, and
because we expected significant heterogeneity between studies, we used random-effects meta-
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analysis and assessed for heterogeneity using the I-squared statistic. To allow combining of
post-intervention and change scores for outcomes, and since outcomes were reported consis-
tently, we calculated the unstandardised difference in means (MD) [16].
To assess effects across key intervention characteristics, we conducted subgroup analyses
for pharmacological interventions by type of drug category; and for behavioural interventions
by duration (short (6 months) or long (>6 months)), and whether or not interventions
included repeated physical activity. We also conducted univariate random effects meta-regres-
sion using intervention duration as a continuous variable (number of weeks). Both duration
and physical activity have been identified as key components of effective diabetes interventions
in the general population [17].
To explore potential differential effects in people with and without diabetes, we conducted
separate subgroup analyses, for i) studies excluding participants with diabetes, and ii) those
that only included people with diabetes and SMI or did not specify diabetes status. We also
conducted univariate random effects meta-regression using mean HbA1c or fasting glucose at
baseline to explore whether or not this explained some of the heterogeneity among studies
[18].
To investigate possible baseline imbalance observed during data extraction, we repeated the
main meta-analyses using mean difference at baseline [19]. We explored the impact of study
quality and heterogeneity by undertaking sensitivity analyses, using ‘leave-one-out’ analyses to
test if single studies had a disproportionate effect on the results. We used the trim-and-fill
method and inspection of funnel plots to investigate publication and small study bias [20]. The
trim-and-fill analysis adjusts for any funnel plot asymmetry and provides an effect size esti-
mate that takes account of observed publication bias.
Comprehensive Meta-Analysis (CMA) version 2 software was used for all statistical
analyses.
Results
A total of 3,721 citations were identified by database searches, and a further 27 articles from
the reference lists of systematic reviews. After removing duplicates, 2,278 records were
screened for relevance by title and abstract, and 197 full text articles retrieved. Of these, 104
did not meet the selection criteria and were excluded. The remaining 93 articles described 73
studies. Nineteen of these were ongoing studies (see S1 Table).
A total of 54 studies were included in the systematic review [21–74]. Six of these studies did
not provide usable data for the meta-analysis [26, 32, 42, 44, 46, 51]. Fig 1 presents a study flow
diagram.
Study characteristics are summarised in Table 1.
Participants
There were a total of 4,392 participants; 2,315 were assigned to intervention and 2,077 to con-
trol arms.
Participants were mainly drawn from mental health outpatient and inpatient settings
(n = 47 studies). One study recruited from supported housing schemes [24], and one from res-
idential care facilities and day programmes [29]. Five studies did not report setting [47, 57, 68,
69, 71].
All but three studies [48, 57, 71] included both men and women, although overall women
were under-represented (41%). Mean age ranged from 25 to 53 years, with a mean age across
studies of 43 years. Ethnicity was poorly recorded, but varied significantly due to the range of
countries included.
Improving Glycaemic Control in Adults with Severe Mental Illness
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Fig 1. Study flow diagram.
doi:10.1371/journal.pone.0168549.g001
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Eighteen studies recruited participants with schizophrenia; 20 with schizophrenia and schi-
zoaffective disorder; two with bipolar disorder; and 14 with various SMIs. The majority of
studies included clinically stable participants who had been diagnosed for several years.
Inclusion of participants with diabetes varied. Only one study specifically recruited people
with type 2 diabetes [29]. Twenty-three studies excluded participants with diabetes (one
excluded type 1 diabetes [59]). The remaining studies did not specify this in eligibility criteria.
Mean HbA1c at baseline ranged from 4.1% to 7.4% (n = 26 studies); 13 studies reported a mean
in the American Diabetes Association (ADA) pre-diabetes category (5.7–6.4%) and two in the
diabetes range (6.5%). Mean fasting glucose ranged from 4.3 to 6.8mmol/L (n = 43 studies);
14 studies reported a baseline mean in the ADA high risk category (5.6–6.9mmol/L) [75].
Thirty studies targeted overweight participants or those who had experienced significant
weight gain. Mean BMI at baseline ranged from 20.2 to 41.9Kg/m2 (n = 49 studies); 41 studies
reported a mean BMI of over 25Kg/m2.
Interventions
Of the 54 RCTs identified, 40 assessed a pharmacological, 13 a non-pharmacological and one a
mixed intervention.
Among the pharmacological studies, 32 used a placebo in the control arm [35–43, 45, 46,
48–55, 57–60, 62, 63, 65–67, 69, 71, 72, 74]. Seven trials evaluated an intervention against usual
care [47, 56, 61, 64, 68, 70, 73]. One study compared two interventions but did not include a
control arm [44].
Among the non-pharmacological studies, six compared an intervention with usual care [21,
22, 25, 27, 30, 32], and three provided basic information or advice to controls at baseline [23,
26, 29]. In one study, the intervention was also given to the control group after week 12 of 24
weeks [28]. Two studies included an active control arm [24, 31]. One trial did not describe the
control intervention [33].
The mixed intervention study included four arms: metformin, metformin plus a lifestyle
intervention, lifestyle plus placebo, and a control arm receiving placebo alone [34].
Pharmacological interventions. In total, 23 different medications from 15 categories of
drug were evaluated (see Table 2).
In nine studies, all participants in intervention and control arms were also enrolled onto a
lifestyle programme [38, 39, 44, 51–53, 58, 69, 70]. In seven further studies all participants had
lifestyle advice at baseline [43, 45, 46, 56], personal wellness counselling [65], limited dietary
intake [74], or mandatory monthly dietary counselling [42]. Details of these interventions and
levels of engagement were not reported.
Intervention duration varied from four weeks to 12 months, being 6 months or less in most
studies.
Non-pharmacological interventions. All 14 non-pharmacological interventions targeted
change in individual behaviour rather than organisation of care. Interventions were variously
described as lifestyle interventions, weight loss programmes and physical exercise pro-
grammes; however, there was considerable overlap between these categories. In total, eight
interventions included regular exercise sessions [23–25, 27, 30, 31, 33, 34] and three restricted
calorie intake [28, 33, 34]. All but one intervention [31] included dietary recommendations,
and all but two [31, 33] employed educational and behavioural strategies promoting a healthier
lifestyle.
Staff delivering interventions varied, but the majority were mental health staff. No interven-
tion specifically included carers of participants, although in one, carers were invited to join a
session [21].
Improving Glycaemic Control in Adults with Severe Mental Illness
PLOS ONE | DOI:10.1371/journal.pone.0168549 January 5, 2017 16 / 31
Table 2. Pharmacological Intervention Categories.
Category and drugs Mechanism of action
Diabetes medication n = 12 [34, 36, 37, 39, 43, 45, 55, 58, 63, 69, 72, 74]
Insulin Diabetes treatment used to regulate carbohydrate and fat
metabolism in the body.
Metformin A biguanide used to prevent and treat Type 2 diabetes by
increasing insulin sensitivity and reducing the amount of
glucose produced and released by the liver.
Pioglitazone, Rosiglitazone Thiazolidinediones help to regulate glucose and fat
metabolism by improving insulin sensitivity, allowing
insulin to work more effectively. Rosiglitazone has been
withdrawn from the EU.
Weight loss medication n = 9 [35, 40, 46, 51–53, 59, 65, 67]
Amantadine A dopamine agonist approved to treat extrapyramidal
side effects and parkinsonian, with potential to decrease
prolactin (plays a role in metabolism) or to decrease
appetite.
Orlistat An anti-obesity drug which acts on the gastro-intestinal
tract by reducing absorption of dietary fat.
Reboxetine An anti-depressant, believed to promote weight loss by
inhibiting serotonin re-uptake and by doing so regulate
eating behaviour and appetite control.
Sibutramine A centrally acting appetite suppressant which has been
withdrawn from the UK and other countries.
Topiramate, Zonisamide Anticonvulsant (epileptic) medication believed to promote
weight loss by stimulating energy expenditure and
decreasing body fat stores (by inhibiting carbonic
anhydrase).
Weight loss and diabetes combination n = 2 [38, 56]
Amantadine + metformin + zonisamide,
Metformin + amantadine + zonisamide
Treatment algorithms of anti-diabetic, anti-parkinsonian
and anti-epileptic medications to allow patients to switch
between treatments depending on clinical response.
Metformin + sibutramine Adding an appetite suppressant to an anti-diabetic may
enhance weight loss potential.
Antipsychotic switching n = 10 [44, 47, 49, 50, 54, 60, 61, 68, 70, 73]
Aripiprazole, Quetiapine, Ziprasidone Switching to or adding an atypical antipsychotic
associated with fewer metabolic side effects is
hypothesised to alleviate weight gain and metabolic
abnormalities caused by the more commonly used
antipsychotics like olanzapine and clozapine.
Olanzapine orally disintegrating The orally disintegrating form of olanzapine is argued to
induce fewer metabolic side effects than the standard
tablet.
Other n = 8 [41, 42, 48, 57, 62, 64, 66, 71]
Crocin, Saffron aqueous extract (SAE) Herbal extracts with the potential to enhance lipid profile
and metabolic function. Crocin is the active ingredient of
SAE.
Dehydroepiandrosterone (DHEA) A steroid hormone with systemic anti-atherosclerotic
properties which help to increase insulin sensitivity and
prevent development of metabolic syndrome
components.
Fluvoxamine An anti-depressant used in combination with clozapine
could help to reduce clozapine dose thereby alleviating
APM induced weight gain and metabolic side effects.
Melatonin, Ramelteon Hypnotics used to treat insomnia which act on the
circadian rhythm (normal sleep-wake cycle) and are
believed to be important metabolic regulators.
Memantine Used to treat dementia, memantine has an anti-
depressant like and mood stabilizing effect and is
believed to reduce binge eating episodes and weight.
(Continued )
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Intervention duration varied from 12 weeks to 18 months, with the majority being between
4 and 6 months. Group sessions were provided in 12 interventions, 4 of which also included
individual sessions or follow-up calls. Sessions varied from 30 minutes to 2 hours in length,
with frequency ranging from 3-times weekly to once a month.
Outcomes
Our primary outcomes of interest were HbA1c and fasting glucose.
Nineteen pharmacological studies measured both of these outcomes. A further five measured
HbA1c (one did not provide data) [42], and 16 measured fasting glucose (one did not provide
data [51] and one provided dichotomous data that were not useable in meta-analysis [46]).
Three behavioural studies measured both HbA1c and fasting glucose [24, 29, 30]. One of
these did not provide data for HbA1c [30], and one reported log transformed data for fasting
glucose which were not useable in meta-analysis [29]. One study measured HbA1c only [25],
and the other nine studies measured fasting glucose only (one did not provide data [32] and
one provided dichotomous data that were not useable [26]).
The mixed intervention study only measured fasting glucose.
All studies measured HbA1c and/ or fasting glucose at the end of the intervention period.
Details of the primary outcomes and follow-up period for each study are shown in Table 1.
Risk of bias
The risk of bias assessment for each study is provided in S2 Table. Only one study was assessed
as low risk across all domains [74]. Reporting of trial design was limited in many studies. Attri-
tion was a particular problem for behavioural interventions and also for antipsychotic switch-
ing trials, many of which reported higher discontinuation rates in the intervention compared
to control groups.
Effectiveness of interventions
For HbA1c, six of 28 (five pharmacological and one behavioural), and for fasting glucose, nine
of 48 studies (five pharmacological, three behavioural and one mixed intervention) showed
improvement in the intervention group compared to the control interventions. The remainder
reported no difference between groups (see Table 1).
Meta-analysis
In the 48 trials included, there were a total of 4,052 participants; 2,150 were assigned to inter-
vention and 1,902 to control arms.
Table 2. (Continued)
Category and drugs Mechanism of action
Naltrexone An opioid receptor antagonist believed to promote weight
loss by altering the food reward system disturbed by
APM treatment, in particular decreasing craving for
sweet foods.
Phenylpropanolamine (PPA) A stimulant used as a decongestant and anorectic agent
which has been withdrawn from the UK and other
countries. Its anorexiant actions are thought promote
weight loss.
doi:10.1371/journal.pone.0168549.t002
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Pharmacological interventions. For pharmacological interventions, we pooled data from
22 studies for HbA1c (n = 1515) and 34 for fasting glucose (n = 2536) (see Fig 2).
For HbA1c there was no evidence of a difference between the intervention and control
groups (MD = -0.03%; 95% Confidence Interval (CI) [-0.12, 0.06]; p = 0.52). Results, however,
were heterogeneous (I2 = 69%).
For fasting glucose there was a small but statistically significant improvement of -0.11
mmol/L (95% CI, [-0.19, -0.02]; p = 0.02) for the intervention group compared to controls.
Again, there was heterogeneity (I2 = 57%). Investigation of baseline imbalance (see S1 Fig)
showed that the control group had slightly lower levels of fasting glucose (MD = 0.07mmol/L;
Fig 2. Meta-analysis of pharmacological interventions.
doi:10.1371/journal.pone.0168549.g002
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95% CI, [0.01, 0.14]; p = 0.03), a difference that while statistically significant, was very small,
and if anything would lead to underestimation of the overall effect size.
For subgroup analysis of pharmacological interventions, we used the drug type categories
described earlier (see Table 2). For the ‘diabetes medication’ category, we further subdivided
interventions into ‘metformin’ and ‘other diabetes’ treatment. Meta-analysis (see Table 3)
showed that antipsychotic switching (MD = -0.11%; 95% CI, [-0.18, -0.05]; p = 0.001; I2 = 0%)
and metformin (MD = -0.08; 95% CI, [-0.14, -0.03]; p = 0.004; I2 = 0%) were effective in lower-
ing HbA1c compared to placebo or usual care, albeit with modest effect sizes. For fasting
glucose, only metformin was effective (MD = -0.15mmol/L; 95% CI, [-0.29, -0.01]; p = 0.04;
I2 = 51%).
Subgroup analyses of studies that excluded participants with diabetes at baseline, and those
that did not, showed that pharmacological interventions were effective in lowering HbA1c only
in the mixed population (MD = -0.11%; 95% CI, [-0.21, -0.01]; p = 0.04; I2 = 59%). For fasting
glucose, neither group showed a statistically significant improvement compared to controls
(Table 3). The meta-regression found no association between baseline HbA1c or fasting glu-
cose levels and effect size (see S3 Fig).
To explore this further, we repeated the subgroup analysis for certain categories of pharma-
cological interventions: diabetes medication, weight loss medication and antipsychotic switch-
ing for fasting glucose; and diabetes medication for HbA1c. No group showed statistically
significant improvements compared to controls (Table 3). We observed larger effect sizes in
studies that did not exclude diabetes at baseline for the diabetes medication and weight loss
medication categories, but similar effects for antipsychotic switching (Table 3). We did not
have sufficient data to examine the remaining categories.
Behavioural interventions. For behavioural interventions, we pooled data from three
studies for HbA1c (n = 140) and 10 for fasting glucose (n = 956) (see Fig 3).
Behavioural interventions were not found to be effective in lowering HbA1c, (MD = 0.18%;
95% CI, [-0.07, 0.42]; p = 0.16).
For fasting glucose, there was evidence of a difference of -0.28mmol/L (95% CI, [-0.43,
-0.12]; p<0.001) comparing behavioural interventions with controls. Although there was evi-
dence of heterogeneity (I2 = 46%), 7 of the 10 studies favoured the intervention. Investigation
of baseline imbalance (see S2 Fig) showed that controls had slightly lower levels of fasting glu-
cose (MD = 0.10mmol/L; 95% CI, [-0.02, 0.23]; p = 0.10).
For subgroup analysis and meta-regression of behavioural interventions, we only examined
fasting glucose due to the small number of studies measuring HbA1c. Participants receiving an
intervention that included physical activity showed an improvement in fasting glucose of
-0.33mmol/L (95% CI, [-0.52, -0.14]; p = 0.001; I2 = 55%) compared to usual care (see Table 3).
Participants receiving an intervention for 6 months or less had lower fasting glucose compared
to usual care (MD = 0.23mmol/L; 95% CI, [-0.34, -0.12]; p<0.001; I2 = 0%); interventions of
more than 6 months duration showed an even greater effect, lowering fasting glucose by
0.50mmol/L (95% CI, [-0.74, -0.25]; p<0.001; I2 = 31%), (Table 3). The meta-regression (see
S4 Fig) confirmed that interventions of a longer duration had a greater effect on fasting glucose
compared to usual care (coefficient = -0.006; 95% CI, [-0.01, -0.002]; p = 0.007).
Subgroup analysis of studies that excluded (MD = -0.28mmol/L; 95% CI, [-0.40, -0.15];
p<0.001; I2 = 0%) or did not exclude people with diabetes at baseline (MD = -0.28mmol/L;
95% CI, [-0.53, -0.03]; p = 0.03; I2 = 61%) showed similar statistically significant effects of
behavioural interventions in improving fasting glucose compared to controls (Table 3). How-
ever, the meta-regression (S4 Fig) showed that effect size increased with higher baseline fasting
glucose, suggesting that interventions may be more effective in those with poorer glycaemic
control (coefficient = -0.36; 95% CI, [-0.59, -0.13]; p = 0.002).
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Table 3. Results of Subgroup Analyses.
Subgroup analysis Number of studies Meta-analysis Heterogeneity
Difference in means 95%
confidence
intervals (CI)
Standard error p-valuea I2 (%) p-value
PHARMACOLOGICAL INTERVENTION SUBGROUP ANALYSES
Intervention categories–HbA1c (%)
Metformin 3 -0.08 -0.14 -0.03 0.03 0.004 0 0.81
Other diabetes medications 5 0.15 -0.22 0.53 0.19 0.42 78 0.001
Weight loss medications 3 -0.32 -0.84 0.20 0.27 0.22 86 0.001
Antipsychotic switching 6 -0.11 -0.18 -0.05 0.03 0.001 0 0.86
Weight loss and diabetes combinations 2 -0.02 -0.24 0.20 0.11 0.84 8 0.30
Intervention categories–fasting blood glucose (mmol/L)
Metformin 8 -0.15 -0.29 -0.01 0.07 0.04 51 0.04
Other diabetes medications 5 -0.06 -0.44 0.33 0.20 0.78 45 0.12
Weight loss medications 5 -0.06 -0.44 0.32 0.19 0.77 79 0.001
Antipsychotic switching 9 -0.04 -0.20 0.12 0.08 0.62 45 0.07
Weight loss and diabetes combinations 2 0.04 -0.47 0.56 0.26 0.87 83 0.02
Exclusion of people with diabetes–HbA1c (%)
All pharmacological interventions:
excluding people with diabetes 9 0.14 -0.04 0.32 0.09 0.13 76 <0.001
not excluding people with diabetes 14 -0.11 -0.21 -0.01 0.05 0.04 59 0.003
Diabetes medication interventions (including metformin):
excluding people with diabetes 5 0.18 -0.14 0.50 0.17 0.27 87 <0.001
not excluding people with diabetes 3 -0.11 -0.31 0.09 0.10 0.29 26 0.26
Exclusion of people with diabetes–fasting blood glucose (mmol/L)
All pharmacological interventions:
excluding people with diabetes 19 -0.08 -0.18 0.01 0.05 0.09 52 0.004
not excluding people with diabetes 16 -0.14 -0.31 0.03 0.09 0.12 64 <0.001
Diabetes medication interventions (including metformin):
excluding people with diabetes 10 -0.12 -0.26 0.02 0.07 0.08 53 0.02
not excluding people with diabetes 3 -0.30 -1.12 0.52 0.42 0.48 50 0.13
Weight loss medication interventions:
excluding people with diabetes 2 0.13 -0.08 0.34 0.11 0.21 0 0.48
not excluding people with diabetes 3 -0.23 -0.77 0.30 0.27 0.39 66 0.05
Antipsychotic switching interventions:
excluding people with diabetes 2 -0.04 -0.33 0.24 0.15 0.78 56 0.13
not excluding people with diabetes 7 -0.04 -0.25 0.17 0.11 0.71 51 0.06
BEHAVIOURAL INTERVENTION SUBGROUP ANALYSES
Intervention duration–fasting blood glucose (mmol/L)
Short interventions (6 months or less) 6 -0.23 -0.34 -0.12 0.06 <0.001 0 0.56
Long interventions (longer than 6 months) 4 -0.50 -0.74 -0.25 0.13 <0.001 31 <0.001
Repeated physical activity–fasting blood glucose (mmol/L)
Interventions with repeated physical activity 7 -0.33 -0.52 -0.14 0.10 0.001 55 0.04
Interventions with no physical activity 3 -0.11 -0.36 0.14 0.13 0.40 0 0.85
Exclusion of people with diabetes–fasting blood glucose (mmol/L)
Studies excluding people with diabetes 3 -0.28 -0.40 -0.15 0.06 <0.001 0 0.70
Studies not excluding people with diabetes 7 -0.28 -0.53 -0.03 0.13 0.03 61 0.02
Table footnotes:
a p-values highlighted in bold indicate statistically significant effects at the 0.05 level.
doi:10.1371/journal.pone.0168549.t003
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Sensitivity analyses
Leave-one-out analyses showed that no single study had a disproportionate effect on each of
the main meta-analyses. However, funnel plots showed some asymmetry (see Fig 4), suggest-
ing potential publication bias for both the behavioural and pharmacological literature.
The trim-and-fill analysis suggests there is some evidence of missing studies (shown as
black on the funnel plots in Fig 4).The adjusted effect sizes, accounting for publication bias are
presented in Table 4. Publication bias adjusted effect sizes suggest that pharmacological inter-
ventions reduce both HbA1c and fasting glucose, and behavioural interventions are effective in
reducing fasting glucose but not HbA1c.
Discussion
Summary of evidence
Overall, compared to usual care, both pharmacological and behavioural interventions
improved fasting glucose levels, but not HbA1c in people with SMI, with behavioural interven-
tions showing a larger difference compared with pharmacological interventions. However,
after adjusting for publication bias, there was some evidence that pharmacological interven-
tions may also improve HbA1c. Subgroup analyses showed improvements in HbA1c for anti-
psychotic switching and metformin; and in fasting glucose for metformin. For behavioural
interventions, those that included regular physical activity were more effective in lowering fast-
ing glucose than those that did not. Subgroup analysis and meta-regression showed that inter-
ventions of longer duration resulted in greater improvements in fasting glucose compared to
Fig 3. Meta-analysis of behavioural interventions.
doi:10.1371/journal.pone.0168549.g003
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usual care, and this may help to explain why the small number of studies measuring HbA1c did
not show an improvement, as only one of these was greater than 6 months in duration.
Fig 4. Funnel plots of behavioural and pharmacological studies.
doi:10.1371/journal.pone.0168549.g004
Table 4. Results of Trim-and-fill Analysis.
Analysis Number of
studies










HbA1c (%) 3 0.18 -0.07 0.42 0.20 (-0.01 to 0.41) [5] 0%
Fasting glucose
(mmol/L)
10 -0.28b -0.43 -0.12 -0.32 (-0.46 to -0.17) [12] 46%
Pharmacological
HbA1c (%) 23a -0.03 -0.12 0.06 -0.04 (-0.13 to -0.05) [24] 69%
Fasting glucose
(mmol/L)
35a -0.11b -0.19 -0.02 -0.11 (-0.19 to -0.02) [35] 57%
Table footnotes:
a The China and US sites in Smith (2013) are counted as separate studies.
b Significant at the 0.05 level.
doi:10.1371/journal.pone.0168549.t004
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Some categories of pharmacological interventions (diabetes and weight loss medications),
appeared to have a smaller effect on lowering glycaemic measurements in studies that excluded
people with diabetes at baseline compared to the effect observed in studies that did not. How-
ever, it was not possible to investigate this robustly because of limited data, and the meta-
regression of all pharmacological interventions showed no association between baseline levels
of HbA1c or fasting glucose and effect size. For behavioural interventions, studies that included
participants with higher baseline glucose levels appeared to be more effective in a meta-regres-
sion, although the subgroup analysis showed no difference between studies that excluded
those with diabetes compared to those that did not.
Our findings are consistent with previous meta-analyses. Bruins et al., [7] found a signifi-
cant improvement in fasting glucose levels with lifestyle interventions (standardised MD =
-0.24, 95% CI, [-0.32, -0.10]; p = 0.001; n = 8 studies; I2 = 0%) but did not include HbA1c in
their analysis or explore intervention characteristics. Mizuno et al., [6] explored pharmacologi-
cal strategies to counteract the metabolic side effects of antipsychotic medication, and reported
statistically significant improvements in fasting glucose for metformin (MD = -0.18mmol/L;
95% CI, [-0.35, 0.00]; n = 9 studies; I2 = 73%); and in HbA1c for metformin (MD = -0.08%;
95% CI, [-0.13, -0.03]; n = 3 studies; I2 = 0%) and aripiprazole (MD = -0.65%; 95% CI, [-1.25,
-0.06]; n = 2 studies; I2 = 89%). Our findings were similar but included drugs in addition to ari-
piprazole in the antipsychotic switching group.
In common with these previous reviews, we found the improvements reported in HbA1c
and fasting glucose were modest. However, there was considerable heterogeneity in results.
Differences in effect sizes and direction of effect between studies made it difficult to assess the
overall effectiveness of interventions. Several studies showed a reduction in fasting glucose and
at the same time an increase in HbA1c or vice versa [37–39, 43, 54]. These results are difficult
to explain because logically one would expect a corresponding change, particularly in longer
duration studies which would take account of the time required to alter HbA1c. However,
there are a number of trials that demonstrate that although HbA1c and fasting glucose are well
correlated, they do not always respond in similar ways [76].
For people with SMI, this relationship may be complicated further by the metabolic side
effects of anti-psychotic medication, which will work against interventions designed to
improve glycaemic control [77]. For example, in several of the pharmacological and beha-
vioural intervention studies, fasting glucose or HbA1c increased in both the intervention and
control groups, but with a smaller increase in the intervention group [24, 31, 43, 49, 56].
Through subgroup analysis and meta-regression, we have been able to identify certain inter-
vention and population characteristics that may explain some of the differences in effect
between studies, and identify particular interventions that show the most promise. However,
these findings should be viewed within the context of methodologically limited trials, and for
the antipsychotic switching and behavioural interventions, substantial dropout in follow-up.
Limitations
Although we included a larger number of studies compared with previous reviews, a limitation
of our findings relates to the quantity and quality of evidence included, and the substantial risk
of potential bias identified in included studies. We were also unable to fully explore differential
effects between those with and without diabetes, or to compare our findings to evidence in the
general population because of the lack of data to measure onset of diabetes in those without
diabetes, and diabetic complications in those with diabetes. Previous reviews have also com-
mented on the paucity and poor quality of evidence in this area [10, 14]. Strengths of our
review include a published protocol, robust search, independent screening and data extraction
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by at least two reviewers, and the use of appropriate meta-analytic methods to explore the
results.
Implications for clinical practice
These results suggest that antipsychotic switching strategies, metformin, sustained behavioural
interventions, and behavioural interventions that include regular physical activity offer the
greatest potential to improve glycaemic control in the SMI population. Whilst the effect sizes
were modest, such improvements in glycaemic control can help to avoid onset of diabetes and
attenuate diabetes complications [11], therefore, the small differences reported in key sub-
groups may still be clinically significant. Also, combining pharmacological and behavioural
strategies may incrementally (or perhaps even synergistically) increase effectiveness [34].
However, the effect sizes observed were modest when compared to the general population [18,
78], suggesting that tailored interventions which address the specific challenges faced by peo-
ple with SMI are needed.
In real world settings, the SMI population will face challenges in adhering to new medi-
cations or engaging in sustained behavioural interventions involving attendance at regular
group sessions [23, 79]. These challenges will likely be compounded when implementing
multifaceted interventions. Moreover, we need to reflect carefully before pursuing adjunc-
tive pharmacological therapies in a population for whom polypharmacy is already pro-
blematic; and the potential acceptability of switching from an antipsychotic medication
providing clinical stability to one which may help to improve physical health, but for which
the efficacy in preventing relapse in mental illness is uncertain. These considerations, along
with the sparse evidence base, mean that recommendations for clinical practice remain lim-
ited. Nonetheless, this review does provide some evidence to support current practice of
providing lifestyle interventions and switching to antipsychotics with a better metabolic
profile in people with SMI.
Conclusions
Improving diabetes outcomes in SMI is a global priority, but the evidence-base to guide clini-
cal practice is limited. Despite the challenges described above, a number of pharmacological
and behavioural approaches warrant further exploration. Metformin is already a well-estab-
lished treatment in diabetes [17]. Its use alongside antipsychotic prescriptions to prevent dia-
betes merits further investigation. Switching of antipsychotic medication is also common in
clinical practice. Research is needed to understand which antipsychotics offer the greatest
potential benefit, and to optimise dosage and timing of such interventions in order to reduce
glycaemic burden, whilst maintaining clinical stability for people with SMI.
Behavioural interventions show perhaps more promise than pharmacological strategies, but
little is known about the behaviour change techniques that might be most effective for people
with SMI and diabetes. This is a key area for research, if we are to avoid ever-increasing
inequalities in health and access to healthcare, as diabetes management becomes increasingly
predicated on self-management. Future research should focus on the design of appropriate
interventions, and test the potential acceptability and feasibility of delivering them in a real
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